Please assess the completion status of the following clinical trial:

Trial Title: Investigation of Bioequivalence of Ethinylestradiol (EE) and Drospirenone (DRSP) in Two Different Tablet Formulations: YAZ and YAZ + Levomefolate Calcium (Metafolin) & L-5-MTHF in Two Different Tablet Formulations: Levomefolate Calcium (Metafolin) and YAZ + Levomefolate Calcium (Metafolin)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy female volunteer~* Age: 18 - 38 years inclusive~* Body mass index (BMI)1: ≥ 19 and \< 28 kg/m²~* Regular cyclic menstrual periods at screening OR when using combined oral contraceptives during the recruitment period reporting of natural cyclic menstrual periods prior to their use~* Willingness to use non-hormonal methods of contraception during the complete trial OR previous tubal ligation~Exclusion Criteria:~* incompletely cured pre-existing diseases for which it can be assumed that the absorption, distribution, metabolism, excretion and effect of the study drugs will not be normal~* known or suspected sex-steroid influenced malignancies~* endometrial hyperplasia; genital bleeding of unknown origin; uterus myomatosus~* known or suspected tumors of the liver and pituitary~* presence or history of severe hepatic disease as long as liver function values have not returned to normal~* severe renal insufficiency or acute renal failure~* thrombophlebitis, venous / arterial thromboembolic diseases; presence or history of prodromi of a thrombosis~* other conditions that increase susceptibility to thromboembolic diseases~* known neuropsychiatric diseases, especially known or suspected epilepsy, and/ or deficient status of folate or vitamin B12~* use of any other medication within 2 cycles before first study drug administration which could affect the study aim~* use of potassium sparing drugs; use of folic acid containing supplements or medicines or use of any medication within 2 cycles before first study drug administration known to interfere with folate metabolism~* inadequate folate and/or Vitamin B12 status, clinically relevant deviations in red cell folate concentrations

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 38 Years
- Healthy Volunteers: t

Study Arms:
- EE 0.02 mg/DRSP 3 mg (YAZ, BAY86-5300) (Type: EXPERIMENTAL): single oral administration of 1 film-coated SHT00186D tablet (YAZ), containing 0.020 mg ethinylestradiol (EE) + 3 mg drospirenone (DRSP)
- EE 0.02mg/DRSP 3mg/L-5-MTHF Ca 0.451mg (EE20/DRSP/L-5-MTHF Ca) (Type: EXPERIMENTAL): single oral administration of 1 film-coated SHT04532B tablet, containing 0.020 mg ethinylestradiol (EE) + 3 mg drospirenone (DRSP) + 0.451 mg Metafolin (L-5-methyltetrahydrofolate calcium \[MTHF-Ca\])
- L-5-MTHF Ca 0.451 mg (Metafolin) (Type: EXPERIMENTAL): single oral administration of 1 coated SHT04532C tablet, containing 0.451 mg Metafolin (L-5-methyltetrahydrofolate calcium \[MTHF-Ca\])

Based on this trial design, predict the completion outcome and termination type (if applicable).